



OBESITY: The Next Questions

Developers and investors have moved past asking whether obesity can be addressed pharmacologically. Now, they're focused on the next pressing questions. This infographic, using data from Evaluate Omnium, considers the answers.

HOW BIG COULD THE OBESITY MARKET BECOME?

Obesity market size by 2030:



\$66 billion

2024: Key player Eli Lilly breaches a

\$800 billion market cap

WILL INCRETINS CONTINUE TO DOMINATE?

Incretins' share of obesity market sales:



WHAT IS THE PIPELINE WORTH?

The obesity pipeline has grown dramatically in the last couple of years.



Marketed obesity drugs



Obesity pipeline




NVP = Net Present Value

WHICH MECHANISMS OFFER THE GREATEST POTENTIAL?

Novel GLP-1s have a higher probability of technical and regulatory success (PTRS) than the average obesity project.

Probability of Technical and Regulatory Success



WILL INVESTORS BACK SMALL DEVELOPERS?

The obesity race is prompting much dealmaking. In this environment, investors are more than willing to back independent players.


In 2024, Viking Therapeutics raised:

\$630m

through a secondary stock offering

\$550m

in financing from Structure



Explore more questions and answers in the [full report](#).

About Evaluate Omnium

Uncover new insights and opportunities with intelligent forecasting from Evaluate Omnium. Using machine learning to analyse millions of data points, Evaluate Omnium provides powerful visibility into the commercial potential and development risks of pharmaceutical assets across the pipeline, including those that are privately held and at a pre-clinical stage.

Contact us for more information: info@evaluate.com